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Relative potencies for 30 compounds scheduled for carcinogenic testing in the 2-year rodent
bioassays were estimated based on comparisons with a wide variety of bioassay data for
benzo[alpyrene, nicotine, cisplatin, aflatoxin B1, and cyclophosphamide. Potential for oncogenic
transformation of each of the compounds was estimated from short-term bioassays. Promoting
strength was assigned on the basis of comparisons of the product of relative potency and test
dose with the distribution of similar products obtained for 67 common compounds in the data-
base of Gold et al. A potency class for promotion was assigned on the basis of whether the
potency-adjusted test dosage was > 2a below the mean, > 1 a below the mean, within ±a of the
mean, > a above the mean, or > 2a above the mean, as determined from the 67 compounds. The
underlying hypothesis is that a weak test dose may have a low probability of revealing a potential
carcinogen, whereas a strong dose may have a high probability of producing false-positive results.
Predictions are therefore directed at the central 68% of the log-normal frequency distribution
according to the assumption that ±a represents the ideal test dose. Environ Health Perspect
104(Suppl 5):1017-1030 (1996)
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Introduction
Goa
The goal of this analysis is to use a wide
variety ofexisting data from several sources
and relative-potency-based models in an
effort to predict the outcome of carcino-
genic testing of rats and mice in the stan-
dard 2-year bioassay as used by the
National Toxicology Program (NTP).
Some of the existing bioassay data are
used to estimate the compound-specific
potential for initiation. For the compound-
specific capacity to promote initiated car-
cinogenic lesions, a large volume of
unedited data are compared to matched
tests for reference carcinogens comprised of
benzo[a]pyrene B[a]P, nicotine, cisplatin,
aflatoxin B1, and cyclophosphamide. In
addition to predicting carcinogenic out-
come ofthe rodent bioassays, rank order is
assigned for the 30 compounds as requested
by the organizers from the National
Institute ofEnvironmental Health Sciences
(NIEHS) and the NTP.
Tennant et al. (1) published an analysis
on "Prediction ofthe outcome ofrodent car-
cinogenicity bioassays currently being con-
ducted on 44 compounds by the National
Toxicology Program." In an editorial in that
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same issue ofMutagenesis, Parry (2) noted,
"Readers will be aware of others who pro-
pose alternative methods for the prediction
of the carcinogenicity of chemicals. I
would like to take this opportunity to open
the debate to other contributors."
Because we have successfully used a
Rapid Screening ofHazard (RASH) chemi-
cal-scoring method for a variety ofdifficult
applications (3-7), it was an excellent
opportunity to test if the RASH-derived
relative-potency estimates could be used for
range-finding for the doses actually tested
in the 2-year bioassays or ifthose estimates
ofrelative potency could be used to predict
the carcinogenic outcome ofthe tests.
Since RASH was based on the hypothe-
sis that toxicity-induced compensatory cell
proliferation may be a practical index of
carcinogenic promotion for toxicological
and radiological insults (8,9), there were
no considerations of potency for carcino-
genic initiation in any of the various
RASH applications other than that by
Jones and Easterly (10). The analysis ofthe
44 compounds (10) avoided the modeling
ofcarcinogenic initiation by using the tab-
ulations by Tennant et al. (1).
This effort will again attempt to
demonstrate the range-finding utility ofthe
RASH method by using data from the
Registry of Toxic Effects of Chemical
Substances (RTECS) (11) and short-term
bioassay data from the NTP to estimate
whether methods described in this exercise
can expedite the NTP range-finding study
by reducing the number of test animals
required to determine the ideal test doses.
Compound-specific relative potency
values and the database of Gold et al.
(12,13) are used to model test doses con-
sidered to be of the proper magnitude to
minimize the probability ofobtaining false-
positive and false-negative test results. This
exercise attempts to demonstrate the utility
of a simple, rapid, data-rich screening tool
and will not resort to careful literature
reviews to refine our initial predictions.
For this analysis, a prototype personal
computer version of RASH (called
CRASH) (5) has permitted more exhaus-
tive relative-potency estimates than were
possible from hand calculations (10,14).
The relative potency from CRASH will be
used in combination with an estimate of
initiation potential as based on short-term
test results to predict which test doses are
too weak to express possible carcinogens,
which test doses are so strong that equivocal
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results or false positives are possible, and
which test doses are just right to produce a
carcinogenic outcome that is consistent
with other NTP test results in the database
ofGold et al. (12,13).
Background
The Environmental Monitoring Plan for
the U.S. Synthetic Fuels Corporation (15)
stated that the corporation should have the
burden ofjustifying the need to monitor
specific unrelated substances and ofprovid-
ing threshold values above which those
substances must be monitored. Somewhat
overlapping in time, the U.S. Air Force
sponsored the development of a hazard
assessment rating methodology (HARM)
that finally became known as the defense
priority model (16,17) for site-specific
screening of the Installation Restoration
Program. Based on observed linear rela-
tionships between carcinogenic risk and
either cytotoxicity or compensatory cell
proliferation for both ionizing radiations
(9,18) and carcinogenic chemicals (8), the
RASH method was proposed for both of
these applications (19).
Method
Because RASH has been documented
exhaustively, it will be summarized very
briefly with somewhat greater detail given to
the differences between the tedious hand
calculations associated with the original
RASH and the prototype personal computer
version used for this application, CRASH.
Jones et al. (14,19) present numerical
demonstrations ofthe RASH evaluations.
RASH. The definition of relative
potency (RP) as used in RASH is the dose
of a reference compound such as B[a]P
divided by the dose of an "interviewing"
compound (i.e., a compound being evalu-
ated) or insult "i" that causes the same
level of response in a common test system,
i.e., RP=DB[alp/Di. In the data used in this
analysis, the doses are the lowest published
values for a positive result in the test of
comparison. The RP index is exactly analo-
gous to the relative biological effectiveness
factors used to compare various ionizing
radiations to a standard such as 250-kVp X-
rays or, to use another analogy, to an elec-
tric motor rated in terms ofhorsepower.
In this manner, it is possible to compute
an equivalent toxic dosage of an interview-
ing compound about which little is known
regarding carcinogenic or human risk in
terms ofa standard or reference compound
for which the carcinogenic or human dose
response is reasonably well known. For the
linear model used to estimate carcinogenic
risk, (Risk)B[a]p = (Slope)B[a]pXDB[a]p and
(Risk)i = (Slope)B[a]p X RPx Di. More
extensive discussion of fundamental con-
cepts and other models of risk have been
presented by Finney (20) and Owen and
Jones (7). It is desirable for the reference
compounds to have been tested extensively
in various bioassays so that several relative-
potency values can be computed for each
new compound ofinterest. The median of
the array ofRP values should be a practical
estimate of the composite toxicological
potency (14). The distribution of RP val-
ues and the stability ofthe median provide
useful information about the uncertainty
in doses required to cause different biolog-
ical effects. For most applications, we have
used the interquartile range, i.e., the
spread between the 25th and the 75th per-
centiles, as a practical measure of uncer-
tainty due to random errors and variations
in experimental design.
Most calculations that have been based
on the RASH method have considered
data unselectively from RTECS on muta-
genesis, carcinogenesis, reproductive toxic-
ity, tumorigenesis, acute toxicity, and even
irritation, although the user could select
bioassays considered to be most relevant to
carcinogenic risk. From examples shown in
previous publications, the different cate-
gories of test data for most compounds
usually lead to similar distributions of RP
values (10,14).
In previous analyses based on RASH,
the compound-specific products of
RPxRegulatory Benchmark are reasonably
constant for a variety ofcompounds evalu-
ated by similar considerations. Alternatively,
the empirical behavior can be viewed as an
inverse proportionality between relative
potency and permissible exposure (5,20).
After extensive testing ofthe RASH method
by six investigators, each using assumptions
in accordance with individual professional
and academic backgrounds, the RASH
process has been found to be quite robust to
different users but somewhat less robust to
additional test data, especially when RPs
were computed from small numbers ofpre-
viously matched comparisons.
This particular study is the second appli-
cation ofa CRASH program (5). The stan-
dardization and simplification required for
the Windows version personal computer
program are consistent with the previous
findings in that significant changes from
earlier publications are primarily due to new
test data. Generally this imprecision results
from user-specific choices or variations
associated with standardized algorithms
used in the CRASH program. In contrast,
however, additional test data for a com-
pound (that has previously been tested
only by Ames tests) and one or two rele-
vant tests for acute toxicity may cause esti-
mates to vary by factors of 3 to 10, while
compounds evaluated only from a couple
of mutagenesis assays (perhaps Ames test
results with and without S9 substrate) may
change by factors of 100 or 1000.
CRASH. The CRASH code was
designed to be as similar to the original
RASH method (14) as possible. The goal
was to match each bioassay available for
the interviewing or test compound with a
similar result for one and only one refer-
ence compound. Reference compounds
included B[a]P as a primary standard and
several secondary standards that were some-
times varied from study to study. Whenever
a test result for the interviewing compound
was matched successfully, the calculation
proceeded to the next bioassay without
considering whether matches with other
secondary standards were possible. Because
computers are almost infinitely faster than
humans at matching bioassay results and
computing relative potency ratios, more
comparisons between the interviewing
compound and the several reference com-
pounds provide greater accuracy-pro-
vided that the results of many bioassays
matched to many different primary refer-
ence compounds are used correctly. Used
incorrectly, an impressive degree of preci-
sion is achieved, but the goal for accuracy
is not achieved.
It was recognized from the beginning
that the RASH method did not necessarily
need to match compounds according to
their mechanisms of action because the
definition is analogous to that of work,
namely, force applied and work achieved.
However, the chemical's structure often
controls the selection ofthe bioassays used
to test its potency and it is readily seen that
inorganic compounds are frequently tested
by bioassays and protocols that are uncom-
mon to organics.
For this application, the CRASH analy-
ses will typically be based on matches ofall
the bioassay results for a particular test
compound, with corresponding test results
for each offive reference compounds used
one by one. The median relative potency is
taken for the interviewing compound rela-
tive to a particular reference compound.
This produces five compound-specific
scales, each ofwhich is normalized to unity
for the reference standard. At the next step
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of the analysis, the five scales are standard-
ized to a common scale by normalizing
each to have unit potency for B[a]P.
It is imperative to match individual
bioassays in this or a logically equivalent
manner because if relative potencies are
computed without any balance, Ames
tests and LD50 results will propagate
exponentially in numbers of matches and
dominate the results. This uncharacteris-
tic proliferation of "excessive matches"
usually leads to great precision but can
result in great inaccuracies.
For the same reason and because the
CRASH program may be used by individu-
als who are relatively new to the process, the
CRASH code does not run to completion
when fewer than three matches are found
between a particular test compound and a
specified reference compound. Therefore, 3
of the 30 compounds were computed by
hand according to the RASH methods-
phenolphthalein, sodium xylenesulfonate,
and isobutene.
Initiation. Results from mutation
bioassays are available from RTECS and
from the NTP battery of short-term
screening tests, which was generously
supplied to participants. Both sources will
be used. Ames test results with and without
metabolic activation have a long, complex
trail as possible predictors ofinitiation and
carcinogenesis. Ames test results from
RTECS and from the NTP bioassays will
be taken as one component offive consid-
erations used to judge the probability of
binary initiation, i.e., whether initiation
processes can be successfully completed by
any conceivable test protocol implement-
ing that particular compound. The second
component (indicated by "I" in column
headings of Table 1) is based on NTP
results for chromosome aberrations and sis-
ter chromatid exchanges and RTECS
results for specific locus test; DNA damage,
repair, synthesis, and inhibition ofsynthe-
sis; gene conversion and mitotic recombi-
nation; cytogenetic analysis; sister
chromatid exchanges; mutation in somatic
mammalian cells; and oncogenic transfor-
mation. The third component, considered
more closely related to intracellular
dosimetry (indicated by "II" in Table 1), is
based on NTP results from the mouse
bone-marrow micronucleus assay, and
RTECS data on body-fluid assay; dominant
lethal test; micronucleus test; phage inhibi-
tion capacity; sex chromosome loss and dis-
junction; sperm morphology; and heritable
translocation test. Positive results in this
class without support from the other four
classes are treated as questionable.
In addition, supplemental considerations
were added as seen in Table 1 if existing
RTECS data indicated that the compound
is oncogenic in either animals or humans.
Results given in Table 1 include the overall
estimate (in the right-hand column) based
on the strength of the total evidence for
inducing positive results with respect to
oncogenic transformation.
Although we have postulated that
initiation has a binary, on/off behavior
and is only qualitatively related to carcino-
genic potency (8,9), data gaps for the 30
test compounds cause us to model initia-
tion in a stepwise fashion for this applica-
tion. We do not believe the process actually
behaves in this manner, but based on the
available data, there is a significant proba-
bility that we will not be able to classify a
Table 1. Summary of mutation bioassay results as available from NTP and RTECS for30compoundscurrentlybeing tested in the2-year mouse and rat studies.a
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compound correctly either as an initiator
or as a noninitiator of the carcinogenic
process. Instead ofa graduated probability
scale, we have used a classification schema
based on - for negative; ? for uncertain;
+ for possible; ++ for moderate; and
+++ for strong evidence based compos-
itely on the five classes of data that we
have taken to be relevant to carcinogenic
initiation of cells. This class assignment
will be used in combination with the pro-
motion class, based quantitatively on
potency-adjusted doses.
Promotion. The compound-specific
potency for promotion will be assigned
from the product of the test dose and the
median value of relative potency as esti-
mated from results published in RTECS.
As described above, the CRASH program
was used to compute the relative potency
for each ofthe 30 test compounds relative
to five reference compounds-B[a]P,
nicotine, cisplatin, aflatoxin B1, and
cyclophosphamide. These compounds were
selected because they have provided consis-
tent results in past evaluations and because
they have an abundance of test data
grouped in the RTECS categories of
mutagenesis, reproductive toxicity, tumori-
genesis, and acute toxicity-except for
B[a]P. Four of the reference compounds
are rich in test results for acute toxicity and
seem well-suited to the 30 compounds to
be tested. Estimates of relative potency are
given in Table 2. The relative potencies
within a particular column are all normal-
ized to a potency of unity for the particu-
lar reference compound shown in the
column heading.
Fewer than three matches were identi-
fied for phenophthalein and isobutene, so
those relative potencies were computed by
hand (14). In addition, sodium xylenesul-
fonate was based only on an acute LD50
value (21) resulting from a literature
search; no test datawere listed in RTECS.
Scatter plots for the test compounds
versus the reference compounds, taken two
by two, are shown in Figures 1 and 2. The
six panels of Figure 1 illustrate that differ-
ent reference compounds lead to consistent
results except for compounds that have not
been tested adequately. Outliers indicated
by an asterisk usually result from a small
number of matches involving Ames test
data or other similarly based bioassays. In
this analysis of30 compounds, many ofthe
relevant bioassay data are based on mea-
sures ofacute toxicity. B[a]P is one ofthe
earliest known carcinogenic compounds
and has never been tested comprehen-
sively in assays for acute toxicity. Thus, as
seen in the four panels of Figure 2, the
absence of acute toxicity data for B[a]P
makes it useless in this particular applica-
tion. In contrast, the estimates shown in
the six panels of Figure 1 provide ade-
quate consistency and (when corrected to
a common scale associated with unit
potency for B[a]P) will permit com-
pound-specific estimates of the power of
the promoting dosage given to both sexes
and species.
The data listed in Table 2 were con-
verted to a common scale as seen in Table 3
based on conversion factors of 1, 3.2, 8.2,
8.08, and 1 for B[a]P, nicotine, cisplatin,
aflatoxin B1, and cyclophosphamide,
respectively (5). These factors are simply
the median RP values for the individual ref-
erence compounds relative to B[a]P.
The RP values from Table 3 were used
to define a median value as shown in col-
umn 8. That value is reproduced in column
Table2. Potency ofcompounds to be tested relative to reference compounds comprising B[a]P, nicotine, cisplatin, aflatoxin B1, and cyclophosphamide.a
RPto RPto RPto RPto RPto cyclo-
Testcompound benzo[a]pyrene Matches nicotine Matches cisplatin Matches aflatoxin B1 Matches phosphamide Matches
Scopalaminehydrobromidetrihydrate - 0 0.0113 1 0.0092 1 - 0 0.142 1
C.deine 011333 3-.----:- .-- : 0-----:-...:-. .-:-.:-:: 19:-- --.------o.58 2 0.. --:-.048--123
1,2-Dihydro-2,2,4-trimethylquinoline - 0 0.0136 2 0.0178 2 0.0024 3 0.0872 2
Tetrahydrofuran 0.286 1 0.0175 4 0.00347 3 0.00249 4 0.0774 4
iS8uty.: : :q::0 ne. 0 ;8 5 4402.. ..04 10 0.2: 9
Ethylbenzene 0.0563 1 0.00281 3 0.00514 2 0.00307 4 0.0471 4
.h£bprn 40:1-: .:--:: :..:-t. 0.7 4 0-4 2- --38 2 2.97 4
Cobaltsulfateheptahydrate - 0 0.0859 1 0.0443 3 0.0092 1 0.477 2
DO.Y,. N.1. 0.17 4 0.00388 1 .4 2 0 4.--..::.:-.:. 0..04 8.1
Isobutyraldehyde - 0 0.0296 2 0.0269 1 0.005 1 0.167 1
! MlbnmrI oxi - 0 058 4 002812 4 004 2 07
1-Chloro-2-propanol 0.00138 2 - 0 0.086 2 0.000333 2 2.77 2 ,D,JW~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~......i'.'.;''':..... Dieihanolemino 0.0227 1 0.009 7 0,00991 7 0.00343 0 0.0555 7~~~~~~~~~~~~~~~~~~~~.. ...... -.
Phenolphthalein
Sodium xylenesulfonate
F1 laCo-ho 0 5 0 0.0 4: ..85 ... 5:
Primaclone 0.0537 4 0.0148 4 0.0233 6 0.0268 6 0.62 6
Et "heu.lwmnbt1te 0.03 .28 0 009 .083 8 0141
Gallium arsenide - 0 0.00126 1 0.0014 1 0.00202 1 0.0234 1
e .- - ' , ' , , ; ., , ' ',' ,::.' - -.. ' ..''"
Methyleugenol 3.14 2 0.0247 3 0.0982 3 0.00407 3 0.539 5
-- - - - :1-J. 1; 02 1 - 0 2 1- :09 3
Anthraquinone 1 3 0.00416 3 0.00483 6 0.00176 4 0.0537 6
Emodln. 0. :. .. ... .::141883 26: 0.1 5 0.032 5::-.2 5
Citral - 0 0.0162 4 0.00545 3 0.00123 4 0.0596 4
Ai 7::f : :0 :23:: :O; Sodumnt*e008 1 .83 1 0.0418 1 .0 8 0172
Cinnamaldehyde 0.0618 4 0.0225 5 0.0147 7 0.00216 9 0.55 9
Valadh m txi 3" 57 1 1.41 - 0.939 8 0.48 3 5.967
RP, relative potency. "Comparisons involving three or more matches were computed by the CRASH code and matches of one or two bioassays were computed by hand.
Column-specific RPvalues are normalized to unityforthe reference compound listed in the column heading.
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2 ofTable 4 and was used to modify the
maximum test doses (MaxD) shown in
columns 3 to 6 for male rats (MR), female
rats (FR), male mice (MM), and female
mice (FM), respectively. The potency-
adjusted dosages are given in columns 7 to
10 ofTable 4.
Table 5, obtained from methods
described in the appendix, was designed to
use the intrinsic capacity ofa compound's
initiation potential (column 1) and the
power of the test protocol with respect to
promotion, as shown in the column
headings. As seen in Table 5, both consid-
erations were used to predict the sex- and
species-specific test outcomes. From the
method described in the appendix, the pro-
moting class is assigned from the median of
the product of relative potency and test
dosage for a database of67 common com-
pounds in the database of Gold et al.
Classification for capacity to effectively pro-
mote carcinogenesis was assigned according





























































































Figure 1. Scatter plots of potency of 30 compounds relative to one reference compound versus the relative
potency computed by the use of a different reference compound. Panels involve nicotine, cisplatin, aflatoxin B1,













L. ,, ..a ,,
0.01 0.1 1 10
Potency to B[a]P
Figure 2. Comparisons are the same as those described
in Figure 1 except nicotine, cisplatin, aflatoxin B1, and
cyclophosphamide are shown versus B[a]P. Because
B[a]P has inadequate test data on acute toxicity, it is
not useful to analyze this particular list of 30 com-
pounds-many of which are tested mostly by bio-
assays concerned with acute toxicity.
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Table 3. Compound-specific relative potency estimates in Table 2, standardized to a common scale indexed by unit potency forbenzo[a]pyreneYa
Testcompound Benzofajpyrene Nicotine Cisplatin Ailatoxin B1 Cyclophosphamide Median High/Low
Scopalaminehydrobromidetrihydrate -0.03616 0.07544 0 0.142 0.0754 4
Codleine 0.33 03065516 07703741.3.87 40
1.2-Dihydro-2,2,4-trimethylquinoline -0.043'52' 0.14596 0.019392 0.0872 0.0654 8
Nitromethane - 601 0.25338-:-'-- -..0"07651.76 0.570.205, 800
Tetr'ahydrofuran 0.286 0.056 0.028454 0.0201192 0.0774 0.056 10
ot-Vulyroquinone 0.8 .43 021 .3676 0.2 0.294
Ethylbenzene 0.0563 0.008992 0.042148 0.0248056 0.0471 0.0421 6
Ch-lo-roprene 40 0.1415.162 0.291688 2'.97: 1116 200
Cobaltsulfate heptahydrate -0.27488 0.36326 0.074336 0.477 0.319 6
0&CYellow No.11 ~~~~~~ ~~0.1:75O172 0;01:1;48!.:. 0::!:~:::(--:.04-34704 -0.0341 00412
Isobutyraldehyde -0.09472 0.22058 0.0404 0.167 0.131 6
Molybdenumtrioxide - 0.17888. 0.231124- 0.279568 0.78 0.256 4
1-Chloro-2-propanol 0.00138 0 0.7052' 0.0026906 2.77 0.354 2000
Diothanolemine . . 0.022~~~~7 0.088: 0.822 00714005 0.0288. 4
Phenolphthalein -0 0 0 0 0.0303-
Pyridine D0835 .0.047-38 0.13202 00216 0.166 0.0522 5
Sodiumxylenesulfonate -0 -0 0 0.0162-
Furfuryl alcohol. 0.8 .018 0 .536 00980850523 1
Primaclone 0.0537 0.04736 0.19106 0.216544 0.62 0.191 9
Ehlngyclmno buy te .00932 01)7618 0. :415744 0:.055994 0.1194 0.0762 20
Gallium arsenide -0.004032 0.01148' 0.0163216 0.0234 0.0139 6
Isobutene .. . . - 0 0 ~~ ~ ~ ~~~~~~~~~~~~~~0 .00038-
Methyleugenol 3.14 0.07904 0.80524 0.0328856 0.539 0.539 100
OXymet-holone 078-2.02:' 0.509- 0.884 4
Anthraquinone 10.013312 0.039606 0.0142208 0.0537 0.0396 80
EmoWin
.. ....014.21. 1.23M 03885.2: 121000.
Citral -0.05184 0.04469 0.00'99384 0.0596 0.0482 6
Sodiumnitrate 0.0~~ ~ ~~~08 099 .3476 0.02424' 017 ..117 40
Cinnamaldehyde 0.0618 0.072 0.12054 0.0174528 0.55 0.072 30
Vanpadiumpentoxde.5 4:.5127.99 3.8784.. 5.96:45
"Conversion factors were 3.2, 8.2, 8.08, and 1.0 for nicotine, cisplatin, aflatoxin Bl, and cyclophosphamide, respectively.
Table 4. Potency-adjusted maximum test doses for tested animals for the 30 test compounds.8
HP composite MaxDb MaxD MaxD MaxD RPx MaxD RPx MaxD RPx MaxD RPx MaxD
No. (B(a]P scale) MR FR mm FM MR FR mm FM Route Solubility
1. 0.0754 25 25 25 25 1.885 1.885 1.885 1.885 Gay w,alc
2. .8 58 67 .338 327' --22A446 25.929 3.0 2.4 ed w l,diai
3. 0.0654 100 100 10 10 6.54 6.54 0.654 0.654 SkinP
4. 0.05 147 1.69 61 24. 3.3465 154 .127.9Ina w(s)ac
5. 0.056 833 955 1733 1767 46'.648 53.48 97.048 98.952 hnhaI w(miscL,alc,ketone,HCs
6.' -0229.:: 182 21-0 563 5451 4.7:4.9 12.2 124.85 Fe
7. 0.0421 511 586 1063 1083 21.5131 24.6706 44.7523 45.594 Inhal' w(ins), org solv
8.- 1.16 46: 53' 95 97- -53.38 81.48.' 102 11.2 .nha org
... olv
9. 0.319 0.47 0.54 0'.98 1 .0.14993 0.17226 0.316 0.319 Inhal
10O. '013341' 182- 210- N-T NT 802 711 --Fe w(fsoi,thnla)
11. 0.'131 925 1061 1925 1963 121.175 138.991 252.175 257.153 Inhal w, ethanol (misc)
1.2;.:::. 0.258: 16 18 .33 406 4888.A44 8A48Ihal w
13. 0.354 34 35 152 159 12.036 12.39 5.808 56.28 Water w,alc
14. 0.288 64 32 160 160 1.432 .918 460 480 kin '(misc), methanol
15. 0.0303 1817 2100 1351 113018 55.'0551 63.63. 40.9353 39.6324 Feed w(ins). alc
18. 0.522 2 21 15 80 10962 10962 7.934 4.17.Wate w(mic a"c oil,org-liq
17. 0.0162 240 240 727 727 3.8 .888 11.7774 11.7774 ...SkinP.
18. 0.523 20 23 42 43 10.48 12.029 21.~~~ ~ ~~~~~966. 2249 na wmiscL.aic
19. 0.191 91 105 146 14`2 17.381 20.055 27.886 27.122 Feed W(SS)
20.: 0.076. 95:. 10V 39 40B2.28.4-'' -2994 35Ina w
21. 0.0138 0.16 0.18 0.33 0.33 0~~~~O.002208 0.002484 0.004554 0.004554 Inhal 22. 0.'00388 87 30 59870. 616 1.8761317 23.29832.612 Ina' (n) I
23. 0.539 150 150 75 75 80.85 80.85 40.425 40.425 Gay
24. 0.884- 15 10 T N-T-::.:' -:1:32-.6:: 88a--. 3v inabolic steroid
25. 0.0396 a a a a ----Feed w(in's),alc
26.-: 123 45, 53 68 65 5525 5.19 !83`64 79.9. Fed wist.al
27. 0.0482 909 1050 2814 2724 43.83 5.61 135.6348 131.2968 Micro w(ins). oil, alc(misc)
28 .117 15 10 46 48 1.3 82 5.5 598 Wtr w i a) acid(decop)
29.. 0.072.. b b b b ----Micro w(dissolv), oil, alc (misc)
30. 4.51 ~~~~~~0- 2 1'--:- 163-::~~'.31. 031.96- 2 .3981 .28 889 9.02 'nal W,-acid,alkaline
MaxD), maximum test dose; MR, male rats; FR, female rats; MM, male mice; FM, female mice; NT, not tested; gay, gavage; skinP, skinpatch; inhal, inhalation; micro, microen-
capsulated chemical in feed; w, water; alc, alchol; dil, dilute; ss, slightly soluble; misc, miscible; HCs, hydrocarbons; ins, insoluble, org. organic; solv, solvent; liq, liquid;
decomp, decomposes; dissolv, dissolves; -, no value for this cell. "Entries shown as "a" and "b" indicate that NTP test doses are notyet available for,anthraquinone and cin-
namaldehyde. bDoses are in milligram per kilogram perday.
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Results, Discussion,
Conclusions
Organizers of this activity requested that
each participant include qualitative predic-
tion (+,-, or equivocal); estimate ofcarcino-
genic potency (1 = least potent to 10 = most
potent); mechanism of carcinogenicity
(genotoxic or nongenotoxic); likely sites of
tumor formation in both species; confidence
in level ofprediction; primary determinant
Initiation Promotion potential of treatment to rats and mice
class (Based on log-normal with mean [RPxMaxD]=5 mg/kg/day, Y=7X, and 2tT=49Xb
<0.1 0.1-0.7 0.7-35 35-245 >245
mg/kg/day mg/kg/day mg/kg/day mg/kg/day mg/kg/day
- Negative Negative Negative Negative Equivocal
? Negative Negative Negative Equivocal Positive
+ Negative Negative Equivocal Positive Positive
++ Negative Equivocal Positive Positive Positive
+++ Equivocal Positive Positive Positive Positive
RP, relative potency; MaxD, maximum test dose. aThe assigned initiation class in column 1 and the promotion
treatment class as listed in the row of column headings taken together determine the prediction for the outcome
ofthe NTP 2-year testing program in both mice and rats. bData from Gold et al. (12,13).
Table 6. Prediction of 2-year carcinogenesis test results in male rats, female rats, male mice, and female mice for
protocol doses listed in Table 4a
Prediction
Test compound Male rats Female rats Male mice Female mice
Scopalamine hydrobromide trihydrate Negative Negative Negative Negative
Codeine Negative Negative. Negative Negative
1,2-Dihydro-2,2,4-trimethylquinoline Negative Negative Negative Negative
Nitromethane Negative N.e. iagative. Negative Negative.:
Tetrahydrofuran Equivocal Equivocal Equivocal Equivocal
t-Butylhydroquinone Positive Positive..... Positive Positive
Ethylbenzene Equivocal Equivocal Positive Positive
Chloroprene Positive. Pt.iPositive PosPitivei
Cobalt sulfate heptahydrate Negative Negative Negative Negative
D&CYellow. No.'1l1 Positive Postive. NT : NT
Isobutaldehyde Equivocal Equivocal Positive Positive
Molybdenum trioxide Equivocl Equivoal Equivoal Equiocal
1-Chloro-2-propanol Equivocal Equivocal Positive Positive
Diethanolamine Negative NEative: egative NegatiVe
Phenolphthalein Equivocal Equivocal Equivocal Equivocal
Pyridine Positive Positive Positive Positive
Sodium xylenesulfonate Negative Negative Negative Negative
Furfurylalcohol Positive Positive Positive Positive
Primaclone Positive Positive Positive Positive
Ethylene glycol monobutyl ether Negative Negative Negative Negative
Gallium arsenide Negative Negative Negative Negative
Isobutene Negative Negative Negative Negative
Methyleugenol Positive Positive Positive Positive
Oxymetholone Equivocal Equivocal NT: NT
Anthraquinone Dose =? Dose=? Dose=? Dose =?
Emodin Positive Positive Positive Positive
Citral Equivocal Equivocal Equivocal Equivocal
Sodium nitrate Positive Positive Positive Positive
Cinnamaldehyde Dose =? Dose =? Dose =? Dose =?
Vanadium pentoxide Negative Negative Negative Negative
NT, not tested. aTest doses have yet to be determined for anthraquinone and cinnamaldehyde but according to our
analysis would preferably be in the range of 17 to 880 mg/kg/day for anthraquinone and 10 to 490 mg/kg/day for
cinnamaldehyde. Once the NTP test doses are determined, our prediction for carcinogenesis can be completed by
potency-adjusted test doses as described in Table 5.
ofprediction (biological and/or chemical);
and relevant comments pertaining to route
ofadministration, exposure dose, chemical
stability, solubility, alteration in gene
expression, etc. The simple chemical
screening tools that we have adapted from
analyses of historical databases are com-
pletely inadequate for such predictive
detail. We have experienced reasonable
success with analyses of dose-magnitude
type considerations (above). Because our
concern has been for issues of risk to
human health, we previously assumed that
cellular initiation was a pervasive condi-
tion. In contrast, animals tested under the
NTP protocols are isolated in test environ-
ments where initiation stressors are mini-
mized. For those tests, simply assessing the
promoting efficacy and ignoring initiation
is generally insufficient to predict the out-
come of test results.
This analysis involves the use ofhistorical
data and hypothetical models designed to
test whether data from general toxicologic
bioassays can be used to quantitatively (but
subjectively) assign categories of carcino-
genic initiation and promotion. Promotion
is modeled from the product of the proto-
col test dosage and relative potency, as
computed from RTECS data. Predictions
are made for compounds currently being
tested. The activity is novel with respect to
most conventional approaches in the bio-
logical literature and the organizers should
be commended for putting science on the
line to evaluate just how much general
knowledge has been accumulated from
decades of research (2). Although the rela-
tive potency factors as used in this applica-
tion seem to have a reasonably good degree
of correlation with the maximum doses
tested in the 2-year studies, it is still
unknown whether the considerations used
to evaluate the initiation potential of test
compounds and the compound-specific
median relative potency can be used in
matrix form to predict the outcome of the
2-year test protocols to a helpful degree.
Hence, discussions and conclusions should
probably be left unrecorded until test results
have been reported, as was the procedure for
the previous 44 compounds (22).
To rank the carcinogenic potency of30
compounds, a scale based on deciles was
used. Placement on the scale depends on
index compounds placed at the extremes.
Different rankings would be expected ifthe
ranking were organized only on the range
defined by the 30 test compounds as
opposed to a more general scale with sac-
charine, ethyl alcohol, and vinyl chloride
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ofa particular test compound is >26 below
the mean, > 1 below the mean, within ±(a
of the mean, >ca above the mean, or >2a
above the mean as given by doses shown in
the headings ofTable 5. The combination
of promoting class and initiation class, as
given in Table 5, determines the com-
pound-specific predictions for the 2-year
NTP tests of male and female populations
ofrats and mice, as shown in Table 6.
Table 5. Matrix for prediction of 2-year test protocols.
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near the low end and aflatoxin B1 and
2,3,7,8-TCDD at the upper end.
The median relative potencies (based
on mass) for the 30 compounds varied by
about 1,000-fold (i.e., 4.51/0.00388). In
contrast, the more general range ofthe 101
compounds considered previously (5) var-
ied by a millionfold based on mass units of
dose and twice that based on molar doses.
Respective rankings of the 30 compounds
in both mass and molar units are indicated
according to deciles in Table 7. Also listed
in Table 7 are the decile rankings ofthe 30
compounds on the molar scale as defined
by the list of 101 compounds. On this
broader scale it is noteworthy that 27 ofthe
30 are above the median toxicity of cate-
gory 5, and 4 of the 30 compounds are in
the most toxic decile of 10.
For the NTP bioassays, extraordinary
care is taken to minimize secondary sources
ofcarcinogenic initiation and this article is
our first effort to model carcinogenic initia-
tion. Clearly, the NTP protocol requires
that carcinogenic initiation be treated in a
realistic manner because an on/offbehavior
could turn an otherwise adequate promot-
ing dose into a negative carcinogenic test
result. However, because our interest is still
focused on safety for humans, we provide
potency scales in both mass and molar
units for all 30 of the test compounds in
Table 7, whether or not the compounds
are classified as carcinogens.
Appendix: Use of TD50S
Tested for 67 Compoun
Ideal Test Dosage for R
Experiments: A Range-I
Definitions
Potency used to describe differential toxic-
ity of one substance when compared with
another or the effect caused by one dose
relative to that of a different dosage of the
same substance.
Relative potency: ratio of doses required
to cause the same level of toxic effect in
both frequency and severity.
Unitpotency: indicates that an insult of
study had identical toxicity to the test sub-
stance or dosage.
TD50: dose of a substance that reduces
the number oftumor-free animials by 50%.
MaxD: the highest dose tested in a
2-year study by the NTP.
Table 7. Hazard ranking for carcinogenic promotion based on mass units of dose and molar units.a
Testcompound Massa Molara MaSSb Test prediction
Scopalamine hydrobromide trihydrate 5 7 7 Negative
.......... .....N...v
1,2-Dihydro-2,2,4-trimethylquinoline 4 5 7 Negative
Tetrahydrofuran 4 4 . 7 Equivocal
Ethylbenzene 4 4 6Positive
Cobalt sulfate heptahydrate 7 8 9 Negative
Pheriolphthalein 3~~~~~~~~~~~~~~. ... . quvoa
Psbtriaclonhye 5 7 9 Positive
Methyleugepopnol 7 7 9 Positive
Cienalph haei 56Equivocal
Soimxyenesulfonae 2 14 14 Negative
Pidsctone stm t hurnl scedld7ortstn Pointhve ya
Salummaryeid copudspoiedals ofwell-tiese compounds:~l::~~:~!:::.,.:":i~"~'~.....of. commn.e virnme talcon Poteny adjstmensto oth T50 vaues ern (). Frm tha list 81 cmpouns ha
and maximum doses tested in the NTP published...TD. .values..(13).and 67 of the 2-year rodent~~... ...............
.. ... carcinogenesisprogram. seem. 81 copond.wr included... in. th. dta to.sugges that thremy.eanida.rne ae.heetetdoe were.avaiablt1) of test doses distributed~~~~~~~~~~~~~~~... abou a. pteny- hi gru.o.7.opons.rvie adjusted median of 5 mg/kgday when a reference dataase that.will.be.standard
dosesaqbelown hsrng ae asoiae fro the 7cmponds with... too man false negatives anJrooo M to test doses above this range~~~~~~~~~~~~~~~~~~.... ma create ..... too.....
many false positives. This hypothesis is Each of the 67 compounds is compared 5 7 quivoca developed for~~~~~~~~.. apliato to the. prdcio.iheaho.he5rfrec.oponso
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the basis of a relative potency analysis, as
described for the 30 test compounds ana-
lyzed above. Next, the reference-specific
relative potency values are standardized to
a common scale indexed by a potency of
unity (i.e., 1.0) for B[a]P. The median of
these converted values is used to character-
ize the potency of a particular compound.
The standardized potency scale correlates
well with both the TD50 and the maxi-
mum test doses (MaxD) for the 67 com-
pounds. Finally, the potency-adjusted
TD50 and MaxD values are used to plot a
log-probability frequency distribution.
These distributions are used to determine
the central 68% of the estimates and are
used as the basis for estimating the ideal
test dosage. The results ofthat analysis can
be used either for range finding of NTP
test doses or to estimate if the indepen-
dently determined test dose is too strong or
too weak relative to the MaxD used for the
central tendency (i.e., ±c) of the 67
compounds considered.
Results
Potency values for the 67 compounds
relative to B[a]P, nicotine, cisplatin, afla-
toxin, and cyclophosphamide are given in
Table Al. The values were estimated by
the CRASH personal computer program.
Column-specific results are on different
potency scales. A column ofpotency values
is standardized to unit potency for the ref-
erence compound shown in the column
heading. All potency values were taken as
computed by the CRASH program, and
therefore comparisons involving two or
fewer matches were not considered.
Potency values in Table Al were com-
pared for the different reference com-
pounds taken two by two, as shown in the
scatter plots ofFigure Al. As seen in Figure
Al, estradiol is evaluated inconsistently by
the various reference compounds, probably
because ofits hormone action. Occasionally,
bis-(2-chloroethyl)ether, sodium saccharine,
and vinyl chloride to a lesser degree, strag-
gle somewhat from the central tendency.
In addition, the comparisons involving
B[a]P demonstrate more scatter because of
the absence of acute toxicity data for
B[a]P. Overall, it is clear that order-of-
magnitude precision is typical between
median relative potency estimates based on
each ofthe compounds.
Using the median potency estimates for
each reference compound relative to B[a]P,
the results listed in Table Al can be con-
verted to a common scale as seen in Table
A2. The conversion factors used were 3.2,
8.2, 8.08, and 1 for nicotine, cisplatin,
aflatoxin, and cyclophosphamide, respec-
tively. The median estimate is given in col-
umn 7 and will be used as the characteristic
potency for each of the 67 compounds
listed in column 2. The range ofestimates
is given in columns 8 and 9.
The median potency values from Table
A2 for each of the 67 compounds were
used to produce the scatter plots ofTD50
or MaxD versus RP for rats and mice, as
seen in Figure A2. In Figure A2, the gen-
eral relationship between potency and
either the TD50 or MaxD values seems to
hold. Occasionally, hydrogen peroxide
(90%), bis(chloromethyl)ether, bis-(2-
chloroethyl)ether, and hormone-acting
diethylstilbestrol are outliers on the scatter-
plots. Test results are typically based on 50
animals within a particular sex and species,
so some randomness should be expected.
However, beyond that randomness, there
seems to be some added uncertainty for
chemically reactive compounds that may
bind to sites not directly related to carcino-
genic mechanisms or to sites that act
through hormone receptors.
The potency-adjusted TD50 and MaxD
values were used to plot a log-probability
frequency distribution, as seen in Figure
A3. From Figure A3, we can see that the
data seem reasonably log-normal within
±a of the mean. The results appear to
deviate above linearity for the tails of the
distribution, but this is likely to be a result
ofa bias for selecting suspected hazards for
testing as opposed to random selecting
from the complete inventory of environ-
mental and industrial pollutants.
Fits ofthe log-probability distribution
to mice or rats (shown cumulatively in
Figure A3) and to the combined data set
are given in Table A3. As seen in Table A3,
the central 68% ofthe estimates are within
a factor of 11 for the TD50 data. TheTD50
values may be intrinsically more variable
than the MaxD doses because different
dose-response models were used from com-
pound to compound. This is supported to
some degree by the result that 68% ofthe
MaxD values are within a factor of7.32 of
the distribution mean.
Conclusions
Results from these comparisons suggest that
potency-adjusted doses from past NTP test
protocols may be used for range finding of
ideal test doses for compounds scheduled
for future testing. Alternatively, the
potency-adjusted doses from past NTP
experiments may be used to form an opin-
ion as to whether a protocol test dose deriv-
ing from subchronic test results is within
the acceptable range: too weak, so that false
negative findings may result, or too strong,
so that they may carry the possibility of
causing false positive conclusions.
For simplicity, it is proposed that the
ideal potency-adjusted test dose can be
taken as 5 mg/kg/day, with a 68% confi-
dence interval based on a factor of7. This
range is defined by the 67 compounds eval-
uated. For compounds tested below 5/7
mg/kg/day or above 5x7 mg/kg/day, there
may be a higher frequency of false nega-
tives and false positives. That hypothesis is
applied to the 30 compounds currently
scheduled for testing in the NTP rodent
carcinogenesis bioassays.
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Table Al. Potency values for 67 compounds relative to B[a]P, nicotine, cisplatin, aflatoxin B1, and cyclophosphamide.a
RPto RPto RPto HPto RPtocyclo-
lest compound B[alP Matches nicotine Matches cisplatin Matches aflatoxin B1 Matches phosphamide Matches
Acetamide 0.2 5 0.00141 9 0.00157 9 0.000685 9 0.014 17
Acrylonitrile 011794 23 0.487 12 0.058 18 0.0118 28 0.876 28~~~~~~~~~~~~0 IO."8.6' .2
Aflatoxin Bi 8.08 74 0A496 9 1.53 24 1Self 40 59
Aldrir,' 1.9 040 13 0129 01751 .119
Benzene 0.0324 34 0.0155 14 0.019 16 0.0044 30066 41
Benile .. . 0573 012 5- 0.85 1 .. 10827
Benzo!alpyrene 1 Self 0.24 9 0.0938 34 0.124 76 1.03 73
4Biphertylemine 0.827 22 Inadequate <3 0.149 15 0.0439 210:::!~.. A .5: 23
Bis(2-chloroethyl) ethier' 0.000312 3 I"n'a'dequate <3 0.0003 3 Inadequate <3 0.283 4
Bi(cloomthQeher OM.0 ndeut 3 013 .1
Carbaryl 0.0221 10 0.68 15 0.1 15 0.0.16 18 0.625 17
Cabnetahoride 1 .098 1 0.02 ..9 001015: 0.08 1.5
Chlordane 0.347 3 0.0424 7 0.129 5 0.0175 9 0.8 7
Chloroembucii 3.33 ~~~~~~17 Inadeqae 3 049 2 0.7 9.72-1
Chloroform 0.0182 8 0.0129 8 0.015 11 0.006 16 0.119 22
Cylp ho's phmd 1..FV 60 0241 83 4.3 57. 1 Self
p4p-DOD Inadequate <3 Inadequate <3 Inadequate <3 0.0222 4 0.58 5
p4DE` 0.266 .016 .37 4 0.0129 9 0.4678
DDT 0.0583 12 0.0837 13 0.183 12 0.02 21 0.957 32
Dibutylnitrosamine 0.0633 9 Inadequate <3 0.0183 4 0.00204 19 0.355 15
3,3M'QDicmezdie 0140 Insadeute 3 0197 001 0 02 15
1,2-Dichloroethane 0.0981 18 0.0179 9 0.014 15 0.000854 20 0.132 23
DN,iedfm11 0.51 13 0.529 10 01481 ..3.689 1
DJiethylnitrosamine 0.373 55 0.128 7 0.05 23 0.02 55 01206 50
Oiwhlti[be!to 0.6 2 0.8 2 0.51 .0766 38- 5.885
7,12-OMBA(57-97-6) 1.52 97 0.153 11 0.288 28 0.122 65 2.04 67
Dimethylnitrosamine 0.34 75 0.862 7 0.27 23 0.0498 72 0.995 61
p-Dioxane 0.0005 7 0~.018 4 .05741 5 00031 1 .03 10
Diphenylnitrosamine 0.0202 17 0.0063 5 0.00476 9 0.00263 17 0.11 21
EN.124-76) 0`227, 24 Iaeuat <3 .58..0.37513 14.4: 10
Estradiol 0.52 11 705 6 0.367 5 0.0918 11 13.1 14
Ethylalcohol 0.00442 24 0.00164 22 ~~~~~~~ ~ ~~~~0.0022 1 8: 0.04 20.00596 24
Ethyleimine 2.93 13 1.48 5 0.727 9 0.15 17 11.4 15
Ethylene dibromide 0~.209 2 0458 0.0333 15 00283 .5 3
Ethylenethiourea 0.1 11 0.0273 5 0.0145 6 0.00281 18 0.132 23
Hetac-hlo 0.13 0.0401 3 ndeut.<:.008 -021-4 6
Hexachlorobenzene 0.42 9 0.0169 6 0.0128 5 0.000575 10 0.149 3
Hexechlorobutadiene *.015 . 7 0.334 7 0.0117 10 ~~~~~~~~~~~~~~0.02-.67..:......::::.14 .513
Hexachloroethane 0.00304 3 0.00618 6 0.00147 3 0.000946 5 0.0349 6
Hyrnine039 1 171 .4 .13 0.127- 18. 20 16
Diphenylhiydrazine 0.642 6 Inadequate <3 0.357 3 0.0146 8 0.485 9
Hdoepeoie (9%) 0.549 1 5.26 0110 .84 20 LB1
Kepone 0.729 4 ais5 7 0.118 3 0.00662 7 3A49 9
Lindena ~~~0.-4 9 0389 0.2 9 01132 17 1.116
3-Methylcholanthrene 1 69 1.25 3 0.175 17 0.245 38 3.32 36
Methyl hydrazine ~~0.037-2 4 .524 2 03, 14.: 0.2186:- 9. 6.17- 12
Methyl methanesulfonate 01289 83 0.2 11 0.0606 37 0.0314 68 1.19 85
M.NNG (0257 125. 65 00894 9 034 4 .6 74 2 59
2-Naphthylamine 0.3 35 1 5 0.04 15 0.0475 35 0.825 35
Nisgn mustard' S6Al1 .31 :-6- 15 2.67 22" 0. 37 3. 41
Phenacetin 0.0112 16 0.0109 7 0.0101 11 0.00109 19 0.0423 25
Phenobabital`:: 0.009 23 0.197 00 2 1 .0 10.0312 26
Reserpine 8.5 10 0.733 16 0.524 15 0.245 12 9.33 26
Safrole ~~~~~~0.1156. 30 0.278 0.012- 1.5 0.00562" 26. 0.234 3
Sodium saccharin 0.593 13 o.oii 6 0.00139 6 0.000B45 17 0.0183 18
2_,33.8-TOl 250- 19 8.81 208 5.9 25 1-000'. 27
Tetrachloroethane 0.0282 6 0.0385 4 0.0209 8 0.00329 6 0.19 10
Tetrchiloroethy1ene 0.0.39 5 .02..07 8: 0.0012 .32 11
Thioacetamide 0.226 18 0.0433 4 0.0583 7 0.00208 26 0.128 21
T ....e.i 0.01:4 6 041 0.89 8 .215. 02.87 15
Trichloroethylene 0.0434 17 0.00885 10 0.0127 11 0.00421 14 0.0651 23
2.4,6-Trichlordophnol 0.05 7J 0.8 .35 0.0 .831
Urethane 0.0625 48 0.0045 9 0.0103 20 0.00455 42 0.0421 43
Vinyl chloride ~0I054 4M ndqat 3 006 4 0-,:.000174 1 06 17
Vinylidene chloride 0.0309 6 0.0172 3 0.0111 5 0.0107 6 0.5 11
aihe column-specific potency values are normalized to unit potency for the reference compounds shown in the column headings. "Matches' are the number of common bio-
assays used to compare the row chemical with the reference compound (column).
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Table A2. Reference compounds from Table Al converted to a common scale of relative potency.8
Benzo[a]- Cyclophos-
Test compound pyrene (1) Nicotine (3.2) Cisplatin (8.2) Aflatoxin B, (8.08) phamide (1) Median Minimum Maximum
Acetamide 0.2 0.004512 0.012874 0.00554288 0.014 0.0129 0.004512 0.2
Aco'tkni'trie' 0.0794 a.m4.456 0032 086 046 74 15
AflatoxinBi 8.08 1.5872 12.546 8.08 40 8.08 1.5872 40
Aidrnin:. 1.2 12.9 1)2.342 3.11 1.29 0.634 3.1
B'e'nzene 0.0324 0.0496 a.i15825 0.035552 0.0696 0.0496 0.0324 0.158
Benidn 0.7 0581.87 fO08 088 0.518 0.008`
B[a]P1 0.768 0.76916 1.00192 1.03 1 0.768 1
Bis(2-chloroethyl) ether 0.000312 - 0.00246 - 0.283 0.00246 0.000312 0.283
Bi(hOroMt, .ehe 10 1.0086.... 4.12888 11 01044-1
Carbaryl 0.0221 0.20096 0.82 0.12928 0.625 0.201 0.0221 0.82
Chlordane 0.347 0.13568 1.0578 0.1414 0.8 0.347 0.1357 1.0
Chloroform 0.0182 0~~~~~~~~~~~~O. 0,4128, 0.2U.4848" 0.119 0.0484 0.0182 0.123 Chlorohorphm de1 0.7080.50266032 31 02
p.p'-DDD--- 0.179376 0.58 0.38 0.179 0.58
Dibuylnitrosamine 0.0633 - 0.15006 0.0164832 0.355 0.107 0.16 :0.355 3,'Diclmezdn 014 - 178 .054 0.2 0.23`0.0953 01)7
A,-ihootae008 .52 0.148` ~ 0.00690032 012 000 006 .3
DieThyntoaie0.3783 0.40964 10.41 0.161 0.206 0.373 0.1623 0.41 (liethylstibestr.ol.0.582 0.8448 1.23 0.618928 5.88 0.845 0.562 5.88~~~~~~~~~~~~~~~~~~~~~~~~~~~.............. 7,12-Dimethylbenz[a]anthracene(57-97-6) 1.52 0.4896 2.3616 0.98576 2.04 1.52 0.49 2.36~~~~~~~~~~~~~~~.
Diphenylnitrosamine0.202 0.00160.103032 0.021250430.11 0.0212 0.02016 0.115 ENNG(4245-77-6) 0.227- 21.158 0.303 14.4 7.35 0.227 21.16~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ ...... .... ........ .... ....... ..... ..... .. ....... ..
Ethyl alcohol .0044.2. 0~~~~~~~~~ ~~~~~~~~~.0..24............031.. .)0...0.0525 0..33 0.01817
Etihylenoethiouea 0.91 0570873 0.11489 0.02270482 0.132 0.0874 0.0227 0.132
Dietahlonirobenzene 0.423 0.04086 0.4109 0.00646 00.149 0.105 0.0065 0.422
l4exachlorabutadiene 0.15 1.0688 0.50594 0.215736 1.45 0.506~~~~~2 0.1 1.45
72Diphenyhydranzine ntrae0.6427- -.89 2.9274 0.1157968 2048 0.564 0.118 2.936
Lindane 0~~~w..4 1.086 1.403 .50""8 1.0 Q31.0416 3-Meth ..holathr.n 1 4' 1.351.796332 1.8
2-Napthylntoamine 0.34 3.258 0.3284 0.30388 0.825 0.384 0.34 3.26
Safrole....i.~~~~~11....>si0.156 0.088240.(~~~~~~~4. . 0.04540..9...0......0.09..4...0.04.......234
227.-TQ )20 4280l.96 166. 44 2100 44 20 1885
Tetrachloroethane 0.0282~~~~~~.. 0.1232 0.17138Ai. 0.025832 0.1 0.123. 0.026.16 0.19 Tipetnylnirosamilne 0.02025 0.020728 0.022142 40.01540.02910255 .00
Etrdolahn .10.4 2512 3007314 0.71744 03.80 041 011 2.807
24.6Iroblomph..ol.0.05.01952.0.24 .16168 0'.101633: 01II.083 0.061.024
UEthalimne 0.062 0.0144 0.0846100374 0121.042 0.0421 0.014 01.045 Vinyl chiojide . 0.00547 - 021648 0~~~~~~~~~~~~~~~ ~~~~~~ ~~~~.00140592 0261.. 0.111 0.0014.0.26
Ethyliene chlouriea 0.030 0.05504 0.01910 0.022086505 0.0865 0.0309 0.
8Coverionto co monscae hvin unt pteny fr .BaJ was achieved. by factors...of. 3.2,. 8.2, 8.08, and... 1.0.. for....... niotne.cspatn af.aoxi and.cyc. ohosphmide respecively
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Figure Al. Scatter plots of the potency of 67 compounds relative to 5 reference compounds taken 2 at a time.
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Figure A2. Median relative potency values from Table A2 were compared with the TD50 estimates from Gold et al.
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Figure A3. Cumulative log-normal frequency plots for
potency-adjusted TD50 doses and maximum doses
tested.
Table A3. Fitted values for a log-normal frequency distribution comparing potency-adjusted TD50 and maximum
doses tested for rats, mice, and mice plus rats.a
Untransformed p,
Data fitted Log1o p Loglo v mg/kg/day Untransformed a
RPxTD50 (mouse) 0.299 0.972 2.00 Factor of 9.38
RPxTD50 (rat) 0.0848 1.06 1.22 Factor of 11.5
RPxTD50(both) 0.158 1.04 1.44 Factorof 11.0
RPx MaxD (mouse) 0.84 0.877 6.92 Factor of 7.50
RPxMaxD (rat) 0.499 0.822 3.16 Factor of 6.63
RPxMaxD (both) 0.617 0.865 4.75 Factor of 7.32
aThe "untransformed" values are based on a unit potency for B[a]P.
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